Bibliographic Details
| Title: |
AURORA: A New Dawn. |
| Authors: |
Papanicolaou, Genovefa A, Avery, Robin K, Cordonnier, Catherine, Duarte, Rafael F, Haider, Shariq, Maertens, Johan, Peggs, Karl S, Solano, Carlos, Young, Jo-Anne H, Fournier, Martha, Murray, Rose Ann, Wu, Jingyang, Bo, Tien, Winston, Drew J |
| Source: |
Clinical Infectious Diseases; 12/15/2024, Vol. 79 Issue 6, p1535-1537, 3p |
| Subject Terms: |
HEMATOPOIETIC stem cell transplantation, PROTEIN kinase inhibitors, PATIENT safety, CYTOMEGALOVIRUS diseases, TERMINATION of treatment, CELLULAR immunity, SURGICAL complications, ANTIVIRAL agents, REINFECTION, VALGANCICLOVIR, DRUG efficacy, VIREMIA, GRANULOCYTE-colony stimulating factor, DRUG resistance, NEUTROPENIA |
| Abstract: |
The article discusses the AURORA trial, the first randomized, double-blind study comparing two oral antiviral agents for cytomegalovirus (CMV) clearance. Topics include the limitations of the 8-week treatment period, which was longer than the typical clinical practice of stopping treatment upon viral clearance; the dose interruption or reduction of valganciclovir in patients with grade 3 neutropenia; and the concern regarding treatment-emergent resistance observed during the trial. |
| Database: |
Complementary Index |
